Investor Materials
Annual Report
View an enhanced version of our report on activities & financial performance throughout the year.
The secure way to view our annual materials and to vote your proxy.
View an enhanced version of our report on activities & financial performance throughout the year.
View an enhanced version of details about our annual meeting & matters to be voted upon.
Your vote is important!
Please be sure to vote your shares online now or by phone at 800-454-8683.
June 7, 2023
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including its lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC. In addition, Ambrx has clinical collaborations with multiple partners on drug candidates generated using Ambrx technology.